These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38552564)

  • 1. Predictive value of immediate early response 5 like (IER5L) in the prognosis and immune checkpoint blockade therapy of non-small cell lung cancer patients.
    Wang N; Tan X; Cao S; Liu M
    Pathol Res Pract; 2024 Apr; 256():155270. PubMed ID: 38552564
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Chen X; He YQ; Miao TW; Yin J; Liu J; Zeng HP; Zhu Q
    Int J Gen Med; 2023; 16():5889-5908. PubMed ID: 38106972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ALOX5 in non-small cell lung cancer: A potential therapeutic target associated with immune cell infiltration.
    Zhao Q; Sun Z; Pan Y; Jing Q; Li W; Wang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):311-322. PubMed ID: 37164914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.
    Zhang R; Ma A
    Gene; 2021 Feb; 770():145337. PubMed ID: 33278551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
    Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
    Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer.
    Chen D; Zhang H; Zhao L; Liu X; Xue S; Wu P; Jiang H
    Cell Cycle; 2023 Apr; 22(7):841-857. PubMed ID: 36536539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
    Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
    Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and analysis of expression, prognosis and immune infiltration of WNT gene family in non-small cell lung cancer.
    Wang J; Yang Q; Tang M; Liu W
    Front Oncol; 2022; 12():911316. PubMed ID: 35957916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
    BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of Immune Implication and Prognostic Value of
    Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
    Front Oncol; 2021; 11():798425. PubMed ID: 35047409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
    Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
    Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.